Gizewska Maria, Wilk Malgorzata, Patalan Michal, Mackay Deborah, Peregud-Pegorzelski Jaroslow, Gawrych Elzbieta, Walczak Mieczyslaw, Petriczko Elzbieta, Brodkiewicz Andrzej
Department of Pediatrics, Endocrinology, Diabetology, Metabolic Diseases and Cardiology, Pomeranian Medical University, Szczecin, Poland.
Turk J Pediatr. 2014 Mar-Apr;56(2):177-82.
Beckwith-Wiedemann syndrome (BWS) is a congenital disorder of imprinting caused by epimutations and mutations affecting two imprinted loci on chromosome 11p15. Its clinical features are heterogeneous, including macrosomia, macroglossia, hemihyperplasia, abdominal wall defects, neonatal hypoglycemia, and increased risk of embryonal tumors such as Wilms tumor, adrenocortical carcinoma, hepatoblastoma, and neuroblastoma. The molecular and clinical heterogeneity of BWS makes the diagnosis challenging, but essential, since different etiologies of BWS have different clinical prognoses - most crucially, patients with gain of maternal methylation at imprinting control region type 1 (ICR1) are at significant risk of Wilms tumor or hepatoblastoma. We present three cases of BWS with different symptomatology and two different molecular diagnoses. The authors emphasize the importance of molecular studies in the long-term follow-up of children with BWS, including refinement of phenotype-genotype correlation and its connection with optimal management and tumor surveillance.
贝克威思-维德曼综合征(BWS)是一种由影响11号染色体p15区域两个印记基因座的表观突变和突变引起的先天性印记障碍。其临床特征具有异质性,包括巨大儿、巨舌症、半身肥大、腹壁缺损、新生儿低血糖以及胚胎性肿瘤(如肾母细胞瘤、肾上腺皮质癌、肝母细胞瘤和神经母细胞瘤)风险增加。BWS的分子和临床异质性使得诊断具有挑战性,但又至关重要,因为BWS的不同病因具有不同的临床预后——最关键的是,在印记控制区1型(ICR1)发生母源甲基化增加的患者有患肾母细胞瘤或肝母细胞瘤的显著风险。我们展示了3例具有不同症状学表现和两种不同分子诊断结果的BWS病例。作者强调了分子研究在BWS患儿长期随访中的重要性,包括完善表型-基因型相关性及其与最佳管理和肿瘤监测的联系。